SPEKTRA Dental Lab Merger and What NDX, Spectrum Killian, and Open Implants Mean for Dentists
The dental laboratory business is entering another phase of consolidation, and this one deserves attention. National Dentex Labs, Spectrum Killian, and Open Implants have combined under a new parent company called SPEKTRA. On paper, the logic is compelling. NDX brings one of the largest dental laboratory networks in the country, decades of relationships with dentists and DSOs, and a substantial field sales presence. Spectrum Killian contributes a more standardized manufacturing philosophy built around repeatable processes, centralized quality control, and high end restorative work. Open Implants adds implant components, including products with FDA 510(k) clearance.
Together, those pieces create something broader than a traditional laboratory company. SPEKTRA is betting on vertical integration.
Dentistry has rapidly digitized the front end of restorative care through intraoral scanners, digital treatment planning, guided surgery, chairside milling, and cloud based case communication. Yet the manufacturing side often remains fragmented among laboratories, implant companies, component suppliers, milling centers, and software platforms. If SPEKTRA can connect more of those steps inside one system, the potential benefit to dentists is straightforward. Fewer handoffs can mean better communication, greater consistency, faster turnaround, fewer errors, and potentially lower costs.
The hard part is execution. NDX built much of its value through local laboratories and long standing relationships with dentists. Spectrum Killian has emphasized standardization, process control, and centralized manufacturing. Those models can complement each other, but they can also conflict. Centralize too aggressively and SPEKTRA risks weakening the local relationships that made NDX valuable. Leave every laboratory operating independently and the efficiencies of scale may never materialize.
For practicing dentists, that is the real question. Will SPEKTRA eventually feel like one coordinated organization, or simply a collection of good laboratories operating under one corporate name?
Open Implants may become one of the most strategically interesting pieces. Owning implant components gives a laboratory organization more control over an important part of the restorative supply chain. It can potentially reduce dependence on third party suppliers, improve inventory management, lower costs, speed production, and capture more margin. In implant and full arch dentistry, where a missing component or compatibility problem can derail an entire appointment, those advantages could become meaningful.
But owning the component company is not enough. SPEKTRA must scale production, manage inventory across multiple implant systems, maintain regulatory and quality standards, and convince clinicians and laboratories to use its products. Vertical integration can improve economics, but it can also add complexity, fixed costs, and regulatory responsibility.
The competitive landscape makes the story more interesting. Dandy has approached laboratory dentistry from the opposite direction. Its model begins with the digital workflow, placing scanners and software into practices and connecting them directly to its laboratory ecosystem. Dandy’s published programs are month to month, so describing dentists as contractually locked in would be overstating the case. The stronger point is that Dandy creates switching costs.
Once the scanner, software, staff training, case history, technician communication, and laboratory workflow are embedded in a practice, changing laboratories becomes inconvenient. That can be a powerful advantage. But the scanner is not economically free. The practice is exchanging recurring laboratory volume for access to the hardware and ecosystem. Whether that is a good deal depends on pricing, quality, service, turnaround time, and remake rates.
SPEKTRA approaches the same market from the opposite direction. It starts with technicians, manufacturing capacity, local relationships, and field sales, then tries to build a more integrated digital system around those assets. If laboratory dentistry becomes increasingly dominated by software, automation, and data, Dandy may have the structural advantage. If technician expertise, local service, relationships, and the management of complex restorative exceptions continue to matter, SPEKTRA may be better positioned.
Then there is Glidewell, perhaps the best comparison of all. Glidewell has spent decades integrating laboratory services, materials, implants, chairside technology, education, and manufacturing. It proves vertical integration can work, but also shows how difficult it is to execute. Scale alone is not enough. It requires capital, technical expertise, operational discipline, and years of refinement.
That is why dentists should pay less attention to phrases such as “redefining oral health” and more attention to what happens in the operatory and the business office. Are remakes declining. Is turnaround getting faster. Is quality becoming more consistent. Are implant components easier to source. Are prices competitive. Is technical support improving. Are local laboratory relationships being preserved.
SPEKTRA has assembled an impressive set of assets. NDX brings reach and relationships. Spectrum Killian brings manufacturing discipline. Open Implants brings a potentially valuable vertical integration layer.
The strategy makes sense. The advantage still has to be proven.
Over the next several years, the most revealing numbers may be customer retention, remake rates, turnaround time, major DSO wins, and the percentage of SPEKTRA implant cases using Open Implants components.
As laboratory dentistry consolidates around scale, software, manufacturing, and relationships, which of those will matter most to your practice?
Join the Conversation!